Clinical Trials

Albireo currently is conducting a Phase 3 clinical trial of investigational product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor that is being studied as a treatment for patients with progressive familial intrahepatic cholestasis (PFIC).

The Phase 3 PFIC program includes a single randomized, double-blind, placebo-controlled, multicenter clinical trial and an open-label long-term extension study. The double-blind trial, called PEDFIC1, is designed to enroll approximately 60 patients with PFIC (subtypes 1 or 2), ages 6 months to 18 years, at sites in the United States, Canada, Europe, the Middle East and Australia.

The PEDFIC1 study is currently recruiting. To learn more about participating in the PEDFIC1 clinical trial, please contact medinfo@albireopharma.com or visit the study page on ClinicalTrials.gov.